��Ƶ

Company Announcements

›

News

and

Publications

Stay in the loop

Thank you for subscribing!

Oops! Something went wrong while submitting the form.

atai Life Sciences and ��Ƶ Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose

Results from ��Ƶ’s Phase IIa study of BPL-003 (intranasal 5-MeO-DMT benzoate) for Alcohol Use Disorder to be presented at CPDD 2025

��Ƶ Ltd today announces that clinical and micro-phenomenology data from its Phase IIa study of BPL-003 for AUD will be presented at the 87th Annual Scientific Meeting of the US College on Problems of Drug Dependence (CPDD) from 14 - 18 June 2025 in New Orleans.

atai Life Sciences and ��Ƶ to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic